Orchestra BioMed Holdings, Inc.
OBIO
Rank in Stocks
#14147
Orchestra BioMed Holdings, Inc. operates as an innovative company in the... Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Share Price
$5.70
Last synced: 2026-11-09
Market Cap
$342.60M
Change (1 day)
0.35%
Change (1 year)
39.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Orchestra BioMed Holdings, Inc. (OBIO)
Category
Healthcare
EPS for Orchestra BioMed Holdings, Inc. (OBIO)
EPS as of June 2026 TTM: $-0.99
According to Orchestra BioMed Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $-0.99. At the end of 2025 the company had an EPS of $-1.11, an increase over its 2024 EPS of $-1.66.
EPS history for Orchestra BioMed Holdings, Inc. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.99 | -10.81% |
| 2025 | $-1.11 | -33.13% |
| 2024 | $-1.66 | 12.16% |
| 2023 | $-1.48 | 12.12% |
| 2022 | $-1.32 | 7,035.14% |
| 2021 | $-0.02 | 117.65% |
| 2020 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,681.82% |
US
|
|
| $-7.07 | 614.14% |
US
|
|
| $-5.29 | 434.34% |
AU
|
|
| $12.88 | -1,401.02% |
BE
|
|
| $21.56 | -2,277.78% |
NL
|
Questions about Orchestra BioMed Holdings, Inc.'s earnings per share (EPS)
What is Orchestra BioMed Holdings, Inc.'s earnings per share (EPS)?
Orchestra BioMed Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $-0.99, as of Jun 2026.
What was Orchestra BioMed Holdings, Inc.'s earnings per share (EPS) in 2025?
In 2025, Orchestra BioMed Holdings, Inc.'s earnings per share (EPS) was $-1.11, compared with $-1.66 in 2024.
How has Orchestra BioMed Holdings, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Orchestra BioMed Holdings, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.01) and lowest in 2024 ($-1.66).
How does Orchestra BioMed Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Orchestra BioMed Holdings, Inc.'s earnings per share (EPS) ($-0.99) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.